Trial record 4 of 4 for:
Ventyx
VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05715125 |
|
Recruitment Status :
Terminated
(sponsor decision)
First Posted : February 6, 2023
Last Update Posted : January 8, 2024
|
Sponsor:
Ventyx Biosciences, Inc
Information provided by (Responsible Party):
Ventyx Biosciences, Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis. Approximately 195 eligible participants will take VTX958 Dose A, VTX958 Dose B, or matching placebo (no active drug) for 16 weeks and then move on to a 36 week Long Term Extension (LTE). The study will include 16 weeks of treatment, 36 weeks of LTE, and a 30-day follow-up period.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Psoriatic Arthritis | Drug: Dose A VTX958 Drug: Dose B VTX958 Drug: Placebo | Phase 2 |
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two doses of VTX958 tablets, Dose A and Dose B, in adults with active Psoriatic Arthritis. Approximately 195 participants will be assigned in a 1:1:1 ratio to one of three groups, VTX958 Dose A, VTX958 Dose B, or placebo, for 16 weeks and then move on to a 36 week Long Term Extension (LTE). The study consists of a 30-day screening period, a 16 week double-blind treatment period, 36 weeks of LTE, and a 30 day follow-up period.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 205 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Participants are randomly assigned at the beginning of the study to either Dose A, Dose B, or placebo group, where they stay for the remainder of the study. |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | The study has a double-blind design, meaning that the participant, care provider, and investigator will not know what treatment group each participant has been assigned to. This blinding will last from randomization until the end of the study. |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients With Active Psoriatic Arthritis |
| Actual Study Start Date : | January 31, 2023 |
| Actual Primary Completion Date : | January 2, 2024 |
| Actual Study Completion Date : | January 2, 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Psoriatic arthritis
| Arm | Intervention/treatment |
|---|---|
| Placebo Comparator: Placebo |
Drug: Placebo
Placebo |
| Experimental: VTX958 Dose A |
Drug: Dose A VTX958
Dose A VTX958 |
| Experimental: VTX958 Dose B |
Drug: Dose B VTX958
Dose B VTX958 |
Primary Outcome Measures :
- Proportion of participants achieving 20% improvement in American College of Rheumatology criteria (ACR20) at Week 16 [ Time Frame: Week 16 ]Number of participants reaching ACR20 at week 16, compared to the total number of participants in each cohort
- Incidence of Treatment Emergent Adverse Events (TEAEs) from week 0 through week 16 [ Time Frame: Week 16 ]The number and proportion of participants who have at least 1 TEAE after exposure to the study drug
Secondary Outcome Measures :
- Change from baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) scores at Week 16 [ Time Frame: Week 16 ]HAQ-DI assesses functional ability. It is a 20 question instrument that assesses the degree of difficulty with accomplishing tasks in 8 functional areas (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty) to 3 (inability to perform a task in that area). The overall HAQ-DI score is the mean of the 8 functional area scores and ranges from 0 to 3. Lower scores are indicative of improved functional ability.
- Proportion of participants achieving 75% reduction in the Psoriasis Area and Severity Index (PASI75) score at Week 16, in participants with at least 3% body surface area (BSA) involvement at baseline [ Time Frame: Week 16 ]PASI is used to assess the severity of psoriasis and response to therapy. Each body region is evaluated separately for body surface area percentage of involvement and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement) and for erythema, induration, and scaling, each is rated on scale of 0 to 4 (from none to maximum severity). PASI numeric scores range from 0 (no psoriasis) to 72 (maximal disease). Higher scores indicate more severe disease.
- Change from baseline in Short Form Health Survey - 36 items (SF-36) physical component score (PCS) at Week 16 [ Time Frame: Week 16 ]SF-36 is a 36-item, patient-reported measure of health status and quality of life, which includes 8 domains (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health). Each of the 8 domains contribute in different proportions to the physical component summary (PCS) score and the mental component summary (MCS) score, which are normalized to general US population norms and range from 0 to 100 (where higher scores correspond to a better quality of life).
- Proportion of participants achieving 50% improvement in American College of Rheumatology criteria (ACR50) at Week 16 [ Time Frame: Week 16 ]Number of participants reaching ACR50 at week 16, compared to the total number of participants in each cohort
- Proportion of participants achieving 70% improvement in American College of Rheumatology criteria (ACR70) at Week 16 [ Time Frame: Week 16 ]Number of participants reaching ACR70 at week 16, compared to the total number of participants in each cohort
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosed with Psoriatic Arthritis for 6 months or more prior to Screening
- Documented history or active signs of at least 1 confirmed lesion of plaque psoriasis and/or nail changes attributed to psoriasis
- Active PsA as defined by 3 or more swollen joints and 3 or more tender joints at Screening and Day 1
- Women must not be of childbearing potential or must agree to use a highly effective contraception during the study and for 30 days after the last dose of the study product
- Men with a partner who is of childbearing potential must agree to use condoms during the study and for 90 days after the last dose of study product
Exclusion Criteria:
- Has non-plaque psoriasis at Screening or Day 1
- Has inflammatory bowel disease or active uveitis
- Has a history of chronic or recurrent infectious disease
- Has a known immune deficiency or is immunocompromised
- Has hepatitis B or hepatitis C infection, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), or active tuberculosis (TB) at screening
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05715125
Locations
Show 46 study locations
Sponsors and Collaborators
Ventyx Biosciences, Inc
Investigators
| Study Director: | Matt Cascino, MD | Ventyx Biosciences, Inc |
| Responsible Party: | Ventyx Biosciences, Inc |
| ClinicalTrials.gov Identifier: | NCT05715125 |
| Other Study ID Numbers: |
VTX958-203 |
| First Posted: | February 6, 2023 Key Record Dates |
| Last Update Posted: | January 8, 2024 |
| Last Verified: | January 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Ventyx Biosciences, Inc:
|
TYK2 inhibitor Psoriatic arthritis Ventyx VTX958 Tranquility |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Psoriatic Joint Diseases Musculoskeletal Diseases Spondylarthropathies Spondylarthritis |
Spondylitis Spinal Diseases Bone Diseases Psoriasis Skin Diseases, Papulosquamous Skin Diseases |